Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Non-measurable speckled contrast-enhancing lesions appearing during course of disease are associated with IDH mutation in high-grade astrocytoma patients.

Berberich A, Hielscher T, Kickingereder P, Winkler F, Drüschler K, Riedemann L, Arzt M, Kessler T, Platten M, von Deimling A, Wick W, Sahm F, Bendszus M, Wick A.

Int J Radiat Oncol Biol Phys. 2018 Jul 30. pii: S0360-3016(18)33461-8. doi: 10.1016/j.ijrobp.2018.07.2004. [Epub ahead of print]

PMID:
30071292
2.

Gd contrast administration is dispensable in patients with MS without new T2 lesions on follow-up MRI.

Karimian-Jazi K, Wildemann B, Diem R, Schwarz D, Hielscher T, Wick W, Bendszus M, Breckwoldt MO.

Neurol Neuroimmunol Neuroinflamm. 2018 Jul 16;5(5):e480. doi: 10.1212/NXI.0000000000000480. eCollection 2018 Sep.

3.

Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance.

Merz M, Hielscher T, Hoffmann K, Seckinger A, Hose D, Raab MS, Hillengass J, Jauch A, Goldschmidt H.

Leukemia. 2018 Jul 6. doi: 10.1038/s41375-018-0202-1. [Epub ahead of print] No abstract available.

PMID:
29977018
4.

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.

Mai EK, Hielscher T, Bertsch U, Schlenzka J, Salwender HJ, Munder M, Gerecke C, Dührsen U, Brossart P, Neben K, Hillengass J, Raab MS, Merz M, Baertsch MA, Jauch A, Hose D, Martin H, Lindemann HW, Blau IW, Scheid C, Weisel KC, Goldschmidt H; German-speaking Myeloma Multicenter Group (GMMG).

Leukemia. 2018 Jun 29. doi: 10.1038/s41375-018-0195-9. [Epub ahead of print] No abstract available.

PMID:
29959413
5.

Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients.

Wennmann M, Kintzelé L, Piraud M, Menze BH, Hielscher T, Hofmanninger J, Wagner B, Kauczor HU, Merz M, Hillengass J, Langs G, Weber MA.

Oncotarget. 2018 May 18;9(38):25254-25264. doi: 10.18632/oncotarget.25402. eCollection 2018 May 18.

6.

Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas.

Röhrich M, Huang K, Schrimpf D, Albert NL, Hielscher T, von Deimling A, Schüller U, Dimitrakopoulou-Strauss A, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1573-1584. doi: 10.1007/s00259-018-4009-0. Epub 2018 May 7.

PMID:
29732524
7.

Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.

Katz LM, Hielscher T, Liechty B, Silverman J, Zagzag D, Sen R, Wu P, Golfinos JG, Reuss D, Neidert MC, Wirsching HG, Baumgarten P, Herold-Mende C, Wick W, Harter PN, Weller M, von Deimling A, Snuderl M, Sen C, Sahm F.

Acta Neuropathol. 2018 Jun;135(6):955-963. doi: 10.1007/s00401-018-1844-9. Epub 2018 Apr 7.

PMID:
29627952
8.

A PRDX1-p38α heterodimer amplifies MET-driven invasion of IDH-wildtype and IDH-mutant gliomas.

Wirthschaft P, Bode J, Simon AEM, Hoffmann E, van Laack R, Krüwel T, Dietrich F, Bucher D, Hahn A, Sahm F, Breckwoldt MO, Kurz FT, Hielscher T, Fischer B, Dross N, Ruiz de Almodovar C, von Deimling A, Herold-Mende C, Plass C, Boulant S, Wiestler B, Reifenberger G, Lichter P, Wick W, Tews B.

Int J Cancer. 2018 Mar 26. doi: 10.1002/ijc.31404. [Epub ahead of print]

PMID:
29582423
9.

Toward an integrated map of genetic interactions in cancer cells.

Rauscher B, Heigwer F, Henkel L, Hielscher T, Voloshanenko O, Boutros M.

Mol Syst Biol. 2018 Feb 21;14(2):e7656. doi: 10.15252/msb.20177656.

10.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf IGH, Scheid C, Haenel M, Weisel KC, Goldschmidt H.

Blood Adv. 2017 Dec 27;2(1):1-9. doi: 10.1182/bloodadvances.2017013334. eCollection 2018 Jan 9.

11.

Inhibition of hepatocellular carcinoma growth by blockade of glycosphingolipid synthesis.

Jennemann R, Federico G, Mathow D, Rabionet M, Rampoldi F, Popovic ZV, Volz M, Hielscher T, Sandhoff R, Gröne HJ.

Oncotarget. 2017 Nov 24;8(65):109201-109216. doi: 10.18632/oncotarget.22648. eCollection 2017 Dec 12.

12.

Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation.

Mosebach J, Shah S, Delorme S, Hielscher T, Goldschmidt H, Schlemmer HP, Schönland S, Hegenbart U, Hillengass J.

Haematologica. 2018 Feb;103(2):336-343. doi: 10.3324/haematol.2017.176073. Epub 2017 Dec 7.

13.

Invitation letters increase participation in colorectal cancer screening - results from an observational study.

Zhan T, Hielscher T, Bilge A, Giese T, Schäfer C, Riemann JF, Ebert MP, Belle S.

Z Gastroenterol. 2017 Dec;55(12):1307-1312. doi: 10.1055/s-0043-121347. Epub 2017 Dec 6.

PMID:
29212101
14.

[Focal lesions in whole-body MRI in multiple myeloma : Quantification of tumor mass and correlation with disease-related parameters and prognosis].

Brandelik SC, Krzykalla J, Hielscher T, Hillengass J, Kloth JK, Kauczor HU, Weber MA.

Radiologe. 2018 Jan;58(1):72-78. doi: 10.1007/s00117-017-0299-7. German.

PMID:
28905085
15.

Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group.

Hillengass J, Moulopoulos LA, Delorme S, Koutoulidis V, Mosebach J, Hielscher T, Drake M, Rajkumar SV, Oestergaard B, Abildgaard N, Hinge M, Plesner T, Suehara Y, Matsue K, Withofs N, Caers J, Waage A, Goldschmidt H, Dimopoulos MA, Lentzsch S, Durie B, Terpos E.

Blood Cancer J. 2017 Aug 25;7(8):e599. doi: 10.1038/bcj.2017.78.

16.

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, Weisel KC, Vellenga E, Pfreundschuh M, Kersten MJ, Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Lindemann HW, Bos GMJ, Brossart P, van Marwijk Kooy M, Ypma P, Duehrsen U, Schaafsma RM, Bertsch U, Hielscher T, Jarari L, Salwender HJ, Sonneveld P.

Leukemia. 2018 Feb;32(2):383-390. doi: 10.1038/leu.2017.211. Epub 2017 Jul 4.

PMID:
28761118
17.

Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial.

Huhn S, Weinhold N, Nickel J, Pritsch M, Hielscher T, Hummel M, Bertsch U, Huegle-Doerr B, Vogel M, Angermund R, Hänel M, Salwender HJ, Weisel K, Dürig J, Görner M, Kirchner H, Peter N, Graeven U, Lordick F, Hoffmann M, Reimer P, Blau IW, Jauch A, Dembowsky K, Möhler T, Wuchter P, Goldschmidt H.

Bone Marrow Transplant. 2017 Aug;52(8):1194-1198. doi: 10.1038/bmt.2017.91. Epub 2017 May 15. No abstract available.

18.

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation.

Merz M, Jauch A, Hielscher T, Mai EK, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf I, Scheid C, Haenel M, Weisel K, Goldschmidt H, Hillengass J.

Haematologica. 2017 Aug;102(8):1432-1438. doi: 10.3324/haematol.2017.168005. Epub 2017 May 11.

19.

Hyperosmolarity impedes the cross-priming competence of dendritic cells in a TRIF-dependent manner.

Popovic ZV, Embgenbroich M, Chessa F, Nordström V, Bonrouhi M, Hielscher T, Gretz N, Wang S, Mathow D, Quast T, Schloetel JG, Kolanus W, Burgdorf S, Gröne HJ.

Sci Rep. 2017 Mar 22;7(1):311. doi: 10.1038/s41598-017-00434-y.

20.

DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.

Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, Okonechnikov K, Koelsche C, Reuss DE, Capper D, Sturm D, Wirsching HG, Berghoff AS, Baumgarten P, Kratz A, Huang K, Wefers AK, Hovestadt V, Sill M, Ellis HP, Kurian KM, Okuducu AF, Jungk C, Drueschler K, Schick M, Bewerunge-Hudler M, Mawrin C, Seiz-Rosenhagen M, Ketter R, Simon M, Westphal M, Lamszus K, Becker A, Koch A, Schittenhelm J, Rushing EJ, Collins VP, Brehmer S, Chavez L, Platten M, Hänggi D, Unterberg A, Paulus W, Wick W, Pfister SM, Mittelbronn M, Preusser M, Herold-Mende C, Weller M, von Deimling A.

Lancet Oncol. 2017 May;18(5):682-694. doi: 10.1016/S1470-2045(17)30155-9. Epub 2017 Mar 15.

21.

Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival.

Thole TM, Lodrini M, Fabian J, Wuenschel J, Pfeil S, Hielscher T, Kopp-Schneider A, Heinicke U, Fulda S, Witt O, Eggert A, Fischer M, Deubzer HE.

Cell Death Dis. 2017 Mar 2;8(3):e2635. doi: 10.1038/cddis.2017.49.

22.

Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.

Selt F, Hohloch J, Hielscher T, Sahm F, Capper D, Korshunov A, Usta D, Brabetz S, Ridinger J, Ecker J, Oehme I, Gronych J, Marquardt V, Pauck D, Bächli H, Stiles CD, von Deimling A, Remke M, Schuhmann MU, Pfister SM, Brummer T, Jones DT, Witt O, Milde T.

Oncotarget. 2017 Feb 14;8(7):11460-11479. doi: 10.18632/oncotarget.14004.

23.

Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients.

Breckwoldt MO, Gradl J, Hähnel S, Hielscher T, Wildemann B, Diem R, Platten M, Wick W, Heiland S, Bendszus M.

J Neurol. 2017 Feb;264(2):341-349. doi: 10.1007/s00415-016-8353-3. Epub 2016 Dec 1.

PMID:
27909801
24.

Multiple behavioral factors are associated with occurrence of large, flat colorectal polyps.

Zhan T, Hahn F, Hielscher T, Bilge A, Grüger J, Weers J, Betge J, Gaiser T, Kähler G, Ebert MP, Belle S.

Int J Colorectal Dis. 2017 Apr;32(4):575-582. doi: 10.1007/s00384-016-2717-0. Epub 2016 Nov 28.

PMID:
27896421
25.

Prognostic relevance of miRNA-155 methylation in anaplastic glioma.

Schliesser MG, Claus R, Hielscher T, Grimm C, Weichenhan D, Blaes J, Wiestler B, Hau P, Schramm J, Sahm F, Weiß EK, Weiler M, Baer C, Schmidt-Graf F, Schackert G, Westphal M, Hertenstein A, Roth P, Galldiks N, Hartmann C, Pietsch T, Felsberg J, Reifenberger G, Sabel MC, Winkler F, von Deimling A, Meisner C, Vajkoczy P, Platten M, Weller M, Plass C, Wick W.

Oncotarget. 2016 Dec 13;7(50):82028-82045. doi: 10.18632/oncotarget.13452.

26.

Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.

Merz M, Hielscher T, Seckinger A, Hose D, Mai EK, Raab MS, Goldschmidt H, Jauch A, Hillengass J.

Am J Hematol. 2016 Nov;91(11):E473-E477. doi: 10.1002/ajh.24533. Epub 2016 Sep 3.

27.

Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.

Betge J, Barat A, Murphy V, Hielscher T, Van Grieken NC, Belle S, Zhan T, Härtel N, Kripp M, Bacon O, Cordes M, Kay EW, Verheul HM, Neerincx M, Hennessy B, Hofheinz RD, Gaiser T, Ylstra B, Prehn JH, Lambrechts D, Byrne AT, Ebert MP, Schulte N.

Digestion. 2016;94(3):129-137. doi: 10.1159/000449412. Epub 2016 Oct 19.

PMID:
27756074
28.

Tubular Dickkopf-3 promotes the development of renal atrophy and fibrosis.

Federico G, Meister M, Mathow D, Heine GH, Moldenhauer G, Popovic ZV, Nordström V, Kopp-Schneider A, Hielscher T, Nelson PJ, Schaefer F, Porubsky S, Fliser D, Arnold B, Gröne HJ.

JCI Insight. 2016 Jan 21;1(1):e84916.

29.

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.

Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Brossart P, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H.

Haematologica. 2016 Dec;101(12):e485-e487. Epub 2016 Aug 18. No abstract available.

30.

A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis.

Ríos-Tamayo R, Lupiañez CB, Campa D, Hielscher T, Weinhold N, Martínez-López J, Jerez A, Landi S, Jamroziak K, Dumontet C, Wątek M, Lesueur F, Reis RM, Marques H, Jurczyszyn A, Vogel U, Buda G, García-Sanz R, Orciuolo E, Petrini M, Vangsted AJ, Gemignani F, Försti A, Goldschmidt H, Hemminki K, Canzian F, Jurado M, Sainz J.

Oncotarget. 2016 Sep 13;7(37):59029-59048. doi: 10.18632/oncotarget.10665.

31.

Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma.

Hertenstein A, Hielscher T, Menn O, Wiestler B, Winkler F, Platten M, Wick W, Wick A.

J Neurooncol. 2016 Sep;129(3):533-539. doi: 10.1007/s11060-016-2206-x. Epub 2016 Jul 15.

PMID:
27422128
32.

Molecular driver alterations and their clinical relevance in cancer of unknown primary site.

Löffler H, Pfarr N, Kriegsmann M, Endris V, Hielscher T, Lohneis P, Folprecht G, Stenzinger A, Dietel M, Weichert W, Krämer A.

Oncotarget. 2016 Jul 12;7(28):44322-44329. doi: 10.18632/oncotarget.10035.

33.

Targeting atypical protein kinase C iota reduces viability in glioblastoma stem-like cells via a notch signaling mechanism.

Phillips E, Lang V, Bohlen J, Bethke F, Puccio L, Tichy D, Herold-Mende C, Hielscher T, Lichter P, Goidts V.

Int J Cancer. 2016 Oct 15;139(8):1776-87. doi: 10.1002/ijc.30234. Epub 2016 Jul 7.

34.

Risk Factors for Local Recurrence of Large, Flat Colorectal Polyps after Endoscopic Mucosal Resection.

Zhan T, Hielscher T, Hahn F, Hauf C, Betge J, Ebert MP, Belle S.

Digestion. 2016;93(4):311-7. doi: 10.1159/000446364. Epub 2016 Jun 7.

PMID:
27271329
35.

Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis.

Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, van Landeghem FK, Santi M, van Veelen ML, Van Meir EG, Osuka S, Fan X, Muraszko KM, Tirapelli DP, Oba-Shinjo SM, Marie SK, Carlotti CG, Lee JY, Rao AA, Giannini C, Faria CC, Nunes S, Mora J, Hamilton RL, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognár L, Klekner A, Hortobágyi T, Leary S, Ermoian RP, Olson JM, Leonard JR, Gardner C, Grajkowska WA, Chambless LB, Cain J, Eberhart CG, Ahsan S, Massimino M, Giangaspero F, Buttarelli FR, Packer RJ, Emery L, Yong WH, Soto H, Liau LM, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis MA, Zagzag D, Wheeler H, von Hoff K, Alonso MM, Tuñon T, Schüller U, Zitterbart K, Sterba J, Chan JA, Guzman M, Elbabaa SK, Colman H, Dhall G, Fisher PG, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro AM, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins CE, Rutka JT, Dirks P, Pfister SM, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Ellison DW, Taylor MD.

J Clin Oncol. 2016 Jul 20;34(21):2468-77. doi: 10.1200/JCO.2015.65.7825. Epub 2016 Jun 6.

36.

Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1.

Josupeit R, Bender S, Kern S, Leuchs B, Hielscher T, Herold-Mende C, Schlehofer JR, Dinsart C, Witt O, Rommelaere J, Lacroix J.

Viruses. 2016 May 19;8(5). pii: E138. doi: 10.3390/v8050138.

37.

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.

Baertsch MA, Schlenzka J, Mai EK, Merz M, Hillengaß J, Raab MS, Hose D, Wuchter P, Ho AD, Jauch A, Hielscher T, Kunz C, Luntz S, Klein S, Schmidt-Wolf IG, Goerner M, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Salwender H, Scheid C, Nogai A, Haenel M, Lindemann HW, Martin H, Noppeney R, Weisel K, Goldschmidt H.

BMC Cancer. 2016 Apr 25;16:290. doi: 10.1186/s12885-016-2321-2.

38.

Fully Automated Pulmonary Lobar Segmentation: Influence of Different Prototype Software Programs onto Quantitative Evaluation of Chronic Obstructive Lung Disease.

Lim HJ, Weinheimer O, Wielpütz MO, Dinkel J, Hielscher T, Gompelmann D, Kauczor HU, Heussel CP.

PLoS One. 2016 Mar 30;11(3):e0151498. doi: 10.1371/journal.pone.0151498. eCollection 2016.

39.

Increased microcirculation detected by dynamic contrast-enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma.

Hillengass J, Ritsch J, Merz M, Wagner B, Kunz C, Hielscher T, Laue H, Bäuerle T, Zechmann CM, Ho AD, Schlemmer HP, Goldschmidt H, Moehler TM, Delorme S.

Br J Haematol. 2016 Jul;174(1):127-35. doi: 10.1111/bjh.14038. Epub 2016 Mar 15.

PMID:
26991959
40.

Transcriptional profiling of dendritic cells matured in different osmolarities.

Chessa F, Hielscher T, Mathow D, Gröne HJ, Popovic ZV.

Genom Data. 2015 Nov 26;7:64-6. doi: 10.1016/j.gdata.2015.11.016. eCollection 2016 Mar.

41.

Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.

Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, McLendon RE, Bigner DD, Lipp ES, Perreault S, Cho YJ, Grant G, Kim SK, Lee JY, Rao AAN, Giannini C, Li KKW, Ng HK, Yao Y, Kumabe T, Tominaga T, Grajkowska WA, Perek-Polnik M, Low DCY, Seow WT, Chang KTE, Mora J, Pollack IF, Hamilton RL, Leary S, Moore AS, Ingram WJ, Hallahan AR, Jouvet A, Fèvre-Montange M, Vasiljevic A, Faure-Conter C, Shofuda T, Kagawa N, Hashimoto N, Jabado N, Weil AG, Gayden T, Wataya T, Shalaby T, Grotzer M, Zitterbart K, Sterba J, Kren L, Hortobágyi T, Klekner A, László B, Pócza T, Hauser P, Schüller U, Jung S, Jang WY, French PJ, Kros JM, van Veelen MC, Massimi L, Leonard JR, Rubin JB, Vibhakar R, Chambless LB, Cooper MK, Thompson RC, Faria CC, Carvalho A, Nunes S, Pimentel J, Fan X, Muraszko KM, López-Aguilar E, Lyden D, Garzia L, Shih DJH, Kijima N, Schneider C, Adamski J, Northcott PA, Kool M, Jones DTW, Chan JA, Nikolic A, Garre ML, Van Meir EG, Osuka S, Olson JJ, Jahangiri A, Castro BA, Gupta N, Weiss WA, Moxon-Emre I, Mabbott DJ, Lassaletta A, Hawkins CE, Tabori U, Drake J, Kulkarni A, Dirks P, Rutka JT, Korshunov A, Pfister SM, Packer RJ, Ramaswamy V, Taylor MD.

Lancet Oncol. 2016 Apr;17(4):484-495. doi: 10.1016/S1470-2045(15)00581-1. Epub 2016 Mar 12.

42.

Gene promoter methylation signature predicts survival of head and neck squamous cell carcinoma patients.

Kostareli E, Hielscher T, Zucknick M, Baboci L, Wichmann G, Holzinger D, Mücke O, Pawlita M, Del Mistro A, Boscolo-Rizzo P, Da Mosto MC, Tirelli G, Plinkert P, Dietz A, Plass C, Weichenhan D, Hess J.

Epigenetics. 2016;11(1):61-73. doi: 10.1080/15592294.2015.1137414. Epub 2016 Jan 19.

43.

Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology.

Mai EK, Hielscher T, Kloth JK, Merz M, Shah S, Hillengass M, Wagner B, Hose D, Raab MS, Jauch A, Delorme S, Goldschmidt H, Weber MA, Hillengass J.

Eur Radiol. 2016 Nov;26(11):3939-3948. Epub 2016 Jan 15.

PMID:
26767378
44.

TERT Promoter Mutations and Risk of Recurrence in Meningioma.

Sahm F, Schrimpf D, Olar A, Koelsche C, Reuss D, Bissel J, Kratz A, Capper D, Schefzyk S, Hielscher T, Wang Q, Sulman EP, Adeberg S, Koch A, Okuducu AF, Brehmer S, Schittenhelm J, Becker A, Brokinkel B, Schmidt M, Ull T, Gousias K, Kessler AF, Lamszus K, Debus J, Mawrin C, Kim YJ, Simon M, Ketter R, Paulus W, Aldape KD, Herold-Mende C, von Deimling A.

J Natl Cancer Inst. 2015 Dec 13;108(5). doi: 10.1093/jnci/djv377. Print 2016 May.

45.

Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma.

Weinhold N, Kirn D, Seckinger A, Hielscher T, Granzow M, Bertsch U, Egerer G, Salwender H, Blau IW, Weisel K, Hillengass J, Raab MS, Hose D, Goldschmidt H, Jauch A.

Haematologica. 2016 Mar;101(3):e116-9. doi: 10.3324/haematol.2015.136929. Epub 2015 Nov 26. No abstract available.

46.

The renal microenvironment modifies dendritic cell phenotype.

Chessa F, Mathow D, Wang S, Hielscher T, Atzberger A, Porubsky S, Gretz N, Burgdorf S, Gröne HJ, Popovic ZV.

Kidney Int. 2016 Jan;89(1):82-94. doi: 10.1038/ki.2015.292. Epub 2016 Jan 4.

PMID:
26466317
47.

Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors.

Selt F, Deiß A, Korshunov A, Capper D, Witt H, van Tilburg CM, Jones DT, Witt R, Sahm F, Reuss D, Kölsche C, Ecker J, Oehme I, Hielscher T, von Deimling A, Kulozik AE, Pfister SM, Witt O, Milde T.

Brain Pathol. 2016 Jul;26(4):506-16. doi: 10.1111/bpa.12326. Epub 2015 Nov 26.

PMID:
26445087
48.

The chemokines CCR1 and CCRL2 have a role in colorectal cancer liver metastasis.

Akram IG, Georges R, Hielscher T, Adwan H, Berger MR.

Tumour Biol. 2016 Feb;37(2):2461-71. doi: 10.1007/s13277-015-4089-4. Epub 2015 Sep 18.

PMID:
26383527
49.

Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study.

Merz M, Moehler TM, Ritsch J, Bäuerle T, Zechmann CM, Wagner B, Jauch A, Hose D, Kunz C, Hielscher T, Laue H, Goldschmidt H, Delorme S, Hillengass J.

Eur Radiol. 2016 May;26(5):1404-11. doi: 10.1007/s00330-015-3928-4. Epub 2015 Jul 29.

PMID:
26215436
50.

Frequent co-occurrence of high-grade dysplasia in large flat colonic polyps (>20 mm) and synchronous polyps.

Zhan T, Hahn F, Hielscher T, Betge J, Kähler G, Ebert MP, Belle S.

BMC Gastroenterol. 2015 Jul 10;15:82. doi: 10.1186/s12876-015-0312-4.

Supplemental Content

Loading ...
Support Center